Comparing LFMT and placebo for treating ulcerative colitis

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This pilot trial aims to evaluate the safety and efficacy of lyophilized fecal microbiota (LFMT) compared to a placebo in patients with active ulcerative colitis who are starting treatment with biologics vedolizumab or ustekinumab. The study is a dual-center, randomized, double-blind, placebo-controlled design, enrolling 40 outpatients across two Canadian healthcare centers. Participants will be monitored for their response to treatment and any adverse effects over the course of the trial.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. 18 years of age or older but less than 75 years of age
2. Able to provide informed consent
3. Established ulcerative colitis diagnosis determined by a physician through standard endoscopic and histologic criteria
4. Active UC defined as total Mayo score between 6-12 AND Mayo endoscopic sub-score \>1 with disease that extends 15 cm or more from the anal verge
5. Selected by treating physician for initiation of biologic treatment with either vedolizumab or ustekinumab. Patients must be:

   * Biologic naive; OR
   * Have failed anti-TNF, anti-integrin, anti IL12/23 or oral small molecules
6. Use of effective contraception method for women of childbearing potential for at least 4 weeks prior to receiving study treatment and for the duration of the trial
7. Willing and able to comply with all required study procedures

Exclusion Criteria:

1. Severe UC requiring hospitalization
2. Indeterminate colitis
3. Evidence of or treatment for C difficile infection or other intestinal pathogen, including CMV, within 4 weeks prior to enrollment
4. Evidence of toxic megacolon or gastrointestinal perforation on imaging
5. Abdominal surgery within the past 60 days

   * Neutropenia with absolute neutrophil count \<0.5 x 109/L
   * Peripheral white blood cell count \> 35.0 x 109/L and fever (\>38 degrees Celsius)
   * Planned or actively taking another investigational product
   * Uncontrolled medical conditions such as psychiatric disorders or substance abuse
   * Severe underlying disease such that the patient is not expected to survive for at least 30 days
6. Pregnant or lactating
7. Unwilling to discontinue non-dietary probiotic
8. Antibiotic use in the past 30 days or anticipated need for systemic antibiotic use during study
9. FMT within 3 months prior to enrollment
10. Use of the following medications:

    1. rectal/topical therapy within 2 weeks of screening
    2. cyclosporine, tacrolimus or thalidomide within 4 weeks of screening
    3. tofacitinib within 4 weeks of screening
    4. adalimumab or infliximab within 8 weeks of screening
    5. vedolizumab within 8 weeks of screening
    6. ustekinumab within 12 weeks of screening
    7. prednisone \> 30 mg/d
11. Investigator deems enrolment in the study is not in the best interest of the patient

Where it's running

• University of Alberta Hospital
  Edmonton, Alberta, Canada Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Comparing subcutaneous and intravenous vedolizumab for inflammatory bowel disease with remote monitoring

  This study is testing if a digital health system can help people with inflammatory bowel disease stick to their vedolizumab treatment, whether they receive it through an injection under the skin or through an IV, and how it affects their health over 22 weeks.

  Recruiting at 2 sites Mercy Medical Center · New Orleans, Louisiana and 5 other locations · NCT06750731

• Comparing target therapies for ulcerative colitis after anti-TNFα treatment

  This study is testing how well three different treatments work for adults with ulcerative colitis who haven't improved after their first anti-TNF-alpha therapy.

  Recruiting Humanitas Clinical and Research Center · Mialn, Italy · NCT06691061

• Combining Probiotic VSL#3 with Vedolizumab for Moderate Ulcerative Colitis

  This study is testing if adding a probiotic called VSL#3 to the medication Vedolizumab can help adults with moderate ulcerative colitis feel better.

  Recruiting at 3 sites Phase 4 Second Affiliated Hospital, Zhejiang University, School of Medicine · Beijing, Beijing Municipality and 11 other locations · NCT06609447

• Treatment of Ulcerative Colitis and Crohn's Disease with Vedolizumab

  This study is testing if a new medication called Vedolizumab can help adults with Ulcerative Colitis or Crohn's Disease feel better and stay symptom-free over a year.

  Recruiting at 78 sites Phase 4 Takeda · Birmingham, Alabama and 100 other locations · NCT06581328

• Comparing two drugs and their combination for treating ulcerative colitis

  This study is testing if using a combination of two drugs, infliximab and ustekinumab, can help adults with moderate to severe ulcerative colitis feel better compared to using each drug alone.

  Recruiting Phase 2 Medical University of Lodz · Lodz · NCT06453317

• Long-term vedolizumab treatment for children and teenagers with ulcerative colitis or Crohn's disease

  This extension tests whether continuing subcutaneous vedolizumab is safe and helps children and teenagers with moderate to severe ulcerative colitis or Crohn's disease stay well.

  Recruiting at 12 sites Phase 3 Takeda · Phoenix, Arizona and 46 other locations · NCT06405087

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.